GlaxoSmithKline (GSK): $VBIV VBI Vaccines will collaborate wit...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	898
Posts	148950
Boards Moderated	0
Alias Born	08/13/2010

BottomBounce

Re: Trend-Setter post# 127

Friday, 10/25/2019 11:29:42 AM

Friday, October 25, 2019 11:29:42 AM

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.